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Pulmonary arterial hypertension (PAH), at one time a largely overlooked disease, is now the subject of intense study in many academic and biotech groups. The availability of new treatments has increased awareness of the condition. This in turn has driven a change in the demographics of PAH, with an increase in the mean age at diagnosis. The diagnosis of PAH in more elderly patients has highlighted the need for careful phenotyping of patients and for further studies to understand how best to manage pulmonary hypertension associated with, for example, left heart disease. The breadth and depth of expertise focused on unravelling the molecular pathology of PAH has yielded novel insights, including the role of growth factors, inflammation and metabolic remodelling. The description of the genetic architecture of PAH is accelerating in parallel, with novel variants, such as those reported in potassium two-pore domain channel subfamily K member 3 (KCNK3), adding to the list of more established mutations in genes associated with bone morphogenetic protein receptor type 2 (BMPR2) signalling. These insights have supported a paradigm shift in treatment strategies away from simply addressing the imbalance of vasoactive mediators observed in PAH towards tackling more directly the structural remodelling of the pulmonary vasculature. Here, we summarize the changing clinical and molecular landscape of PAH. We highlight novel drug therapies that are in various stages of clinical development, targeting for example cell proliferation, metabolic, inflammatory/immune and BMPR2 dysfunction, and the challenges around developing these treatments. We argue that advances in the treatment of PAH will come through deep molecular phenotyping with the integration of clinical, genomic, transcriptomic, proteomic and metabolomic information in large populations of patients through international collaboration. This approach provides the best opportunity for identifying key signalling pathways, both as potential drug targets and as biomarkers for patient selection. The expectation is that together these will enable the prioritization of potential therapies in development and the evolution of personalized medicine for PAH.
Introduction
Pulmonary hypertension (PH) has an estimated global prevalence of 1% [1] . It is defined by a resting mean pulmonary artery pressure (mPAP) ≥25 mmHg during right heart catheterization [2] . A mPAP ≥25 mmHg is an independent predictor of survival in a number of clinical presentations, but there is a continuum of risk with borderline PH, classified as mPAP between 19 and 24 mmHg, associated with increased hospitalizations and mortality [3] [4] [5] .
PH is classified into five main groups by international consensus, based on clinical features, including the presence of a coexisting disease, haemodynamic measurements and, increasingly, genetic information [6] (Table 1) . This clinical classification has its limitations as it lacks the granularity needed to tailor treatment based on individual patient phenotypes [7] . Pulmonary arterial hypertension (PAH) is the first main category and characterizes a subgroup of patients with precapillary disease (mPAP ≥ 25 mmHg and Review pulmonary arterial wedge pressure (PAWP) ≤15 mmHg) and increased pulmonary vascular resistance (PVR >3 Wood units). It is inclusive of congenital heart disease and connective tissue disease but excludes chronic thromboembolic disease, hypoxic and interstitial lung disease, and miscellaneous diseases which have their own categories [6] . Patients with idiopathic pulmonary arterial hypertension (IPAH) are the most common form of PAH, and this is a diagnosis of exclusion [6] . PH presents most frequently in association with other diseases, such as left heart disease (PH-LHD) and chronic lung disease [1] . PH-LHD is recognized as postcapillary pulmonary hypertension, from backward transmission of high leftsided filling pressure, and is defined haemodynamically by a mPAP ≥25 mmHg with PAWP >15 mmHg. A significant number of patients with PH-LHD have increased PVR >3 Wood units and a diastolic pressure gradient ≥7 mmHg, suggesting a precapillary component to their pulmonary hypertension.
A multicentre US-based registry for PAH (Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management -REVEAL registry) indicates an incidence and prevalence of 2.0 and 10.6 cases of PAH per million inhabitants, respectively [8] . Registries from the UK show similar incidence and prevalence rates of 1.1 and 6.6 cases of PAH per million inhabitants, respectively [9] .
The currently licensed therapies for PAH target the three main vasoactive pathways, namely -prostacyclin-cAMP, nitric oxide-soluble guanylate cyclase-phosphodiesterase type 5 (cGMP-PDE5) and endothelin [6] . Despite improvement in patient symptoms and well-being with these agents, mortality rates remain high (~65% survival at 5 years) [10] and there is a need for therapies targeting alternative pathways that can reverse pulmonary vascular remodelling, inhibit disease progression and improve survival. The changing demographics and revisiting the haemodynamic classification PAH is seen more commonly in women. The REVEAL registry records a 4:1 female: male ratio [11] , and 72% of patients were female in a recent meta-analysis of 1550 patients with IPAH, hereditary PAH (HPAH) or anorexigen-induced PAH [12] . But the demographics of PAH are changing. Earlier registries record the mean age at presentation as 36 years [13] . Increasingly the diagnosis is made in the elderly population, and current registries show a mean age between 50 and 65 years at diagnosis [6, 9, 11, 14] .
Elderly patients (over 75 years) diagnosed with IPAH have less gender bias than younger patients and a higher mortality, following adjustment for age [15] . Older patients have more comorbidities, with an increased number of risk factors for LHD. This has led to the use of terms such as 'typical IPAH', which refers to patients who have fewer than three risk factors for LHD, and 'atypical IPAH', who have three or more risk factors for LHD [15] .
A comparison of patients with 'typical IPAH', 'atypical IPAH' and pulmonary hypertension associated with heart failure and preserved ejection fraction (HFpEF) has shown similar mPAP, cardiac output and long-term survival [15] . One view expressed is that there is a spectrum of disease ranging from PAH to HF-pEF with combined precapillary and postcapillary (CpC-PH) bridging the two [6, 16] . The lungs of CpC-PH patients exhibit histological evidence of pulmonary vascular remodelling similar to PAH [17] , but, in general, patients with PH-LHD are not responsive to therapies developed for PAH and show a higher incidence of side effects. Current guidelines discourage the use of PAH therapies in patients with HF-pEF and a greater understanding of the molecular drivers of PH in these patients will help develop better treatment strategies [15] .
Pathophysiology -recognizing proliferation, inflammation and metabolic remodelling PAH is characterized by the narrowing of small pulmonary arteries through vasoconstriction, thrombosis, and proliferation and remodelling of the vessel wall [18, 19] . This includes characteristic neointimal and plexiform lesions, and medial hypertrophy, propagated by the proliferative and anti-apoptotic phenotypes of pulmonary endothelial cells, smooth muscle cells, fibroblasts and myofibroblasts [20] . There is also increasing evidence of a transition of pulmonary artery endothelial cells to smooth muscle like mesenchymal cells (endothelial-to-mesenchymal transitioning) which can be driven by dysfunctional bone morphogenic protein receptor type II (BMPR2) signalling [21] [22] [23] , the predominant cause of hereditary PAH [24, 25] . Occlusion of the lumen in small distal pulmonary arteries leads to increased PVR and subsequently increased right ventricular (RV) afterload and RV failure [6, 26] .
Given the pronounced structural remodelling of diseased vessels, it is surprising that little attention has been paid to the potential growth factors involved until relatively recently. The idea that the vascular lesions of PAH exhibit many of the traits of cancer (abnormal and uncontrolled cell growth, angioneogenesis, evasion of apoptosis, self-sufficiency in growth signals and insensitivity to antigrowth signals) and resembles a neoplastic angioproliferative disorder took a while to challenge the prevailing opinion that PAH was the consequence of chronic and sustained vasoconstriction [27, 28] . But the 'cancer paradigm' concept is now firmly established and frames the investigation of many new drug targets and the possibility of repurposing anticancer drugs [29] .
Whilst there is no evidence of constitutively active growth factors in PAH, patient-derived pulmonary vascular cells show an increased proliferative response to mitogenic stimuli, including foetal calf serum, fibroblast growth factor-2 (FGF-2), epidermal growth factor (EGF), vascular endothelial growth factor and platelet-derived growth factor (PDGF), and are less sensitive to apoptosis induction by serum deprivation [29] . Such hyperproliferative potential could be explained by overexpression and/ or activation of receptor tyrosine kinases, including EGF, FGF and PDGF receptors. A clinical trial to investigate the efficacy of the PDGFR inhibitor, imatinib, in PAH suggests that some patients may respond and benefit from this approach, but the development programme has been halted because of side effects and concerns about safety [30] [31] [32] . There remains considerable interest in further targeting growth factors, including PDGF, in PAH.
A role for inflammation in PAH was recognized nearly 25 years ago [33] . Histology of diseased vessels shows a significant influx of inflammatory cells, including macrophages and lymphocytes.
Beyond increased perivascular immune cell accumulation and intravascular infiltration, circulating levels of certain cytokines and chemokines are abnormally elevated [34] . These include interleukin (IL)-1b, IL-6, IL-8, monocyte chemoattractant protein-1, fractalkine, chemokine ligand 5/regulated on activation normal T cell expressed and secreted (CCL5/RANTES) and tumour necrosis factor-a.
More recently lymphoid neogenesis has been implicated in the vascular remodelling process in the lungs of PAH patients [35] . Whether inflammation is a key driver of PAH or part of the healing process merits pause for thought, but the evidence is in favour of the former; some of these cytokines and chemokines correlate with a worse clinical outcome in PAH patients and may serve as biomarkers of disease progression. A definitive answer awaits an anti-inflammatory intervention that changes the course of the disease for the better.
Metabolic remodelling is also a feature shared by vascular cells in PAH and cancerous cells [36] [37] [38] [39] [40] . Central to this is energy metabolism in mitochondria [37] . Proliferating cells exhibit a shift to aerobic glycolysis, mediated predominantly by pyruvate dehydrogenase kinase (PDK), which inhibits pyruvate dehydrogenase [40] . This has been reported in both the pulmonary vasculature and the right ventricle in PAH [41] . Evidence of increased metabolites from the tricarboxylic acid (TCA) cycle and fatty acid oxidation, and altered arginine and sphingosine pathways have been found from mass spectrometry analysis of lung tissue from PAH patients [42, 43] . Restoration of glucose oxidation, either directly or by exploiting the Randle cycle to decrease fatty acid oxidation and glutaminolysis, provides a potential therapeutic target for patients with PAH ( Fig. 1) . As an exemplar of this approach, administration of dichloroacetate (DCA) to directly inhibit PDK improves both pulmonary vascular disease and right ventricular function in animal models of PAH [44] [45] [46] [47] and is currently under investigation in patients with PAH (http://www.clinicaltrials.gov; NCT01083524).
Several other metabolic pathways have been implicated in the pathobiology of pulmonary arterial hypertension, including steroid [48] , arginine [43, 49, 50] , polyamine [43, 51, 52] , tryptophan [53] [54] [55] and sphingolipid metabolism [56] . Metabolic profiling of patients is an active area of research with increased circulating acylcarnitines [57, 58] and modified nucleosides originating from transfer RNAs seen in patients with PAH and linked to survival [57] .
Genetic susceptibility to pulmonary arterial hypertension
The observation that mutations in BMPR2 increased susceptibility to PAH came from family studies reported in 2000 [59, 60] . A recent meta-analysis of 1550 patients with idiopathic, heritable or anorexigen forms of PAH found BMPR2 mutations in 29% of participants [12] . Mutations were seen in 82% of patients with a family history and in 17% of cases with no known family history of the disease. BMPR2 mutation carriers had an earlier onset of disease and higher mPAP and higher PVR. They also had poorer outcomes related to survival and transplantation [12] . Pathogenic mutations have been found throughout the BMPR2 gene, including key regions such as the kinase domain [61] . Despite the importance of BMPR2 in the pathobiology of PAH, disease penetrance in carriers is only~20%, indicating that other genetic and/or environmental factors are required for development of the phenotype.
BMPR2 is a receptor for multiple bone morphogenetic proteins and acts to suppress vascular smooth muscle cell growth through the intracellular Smad and LIM (Lin-11, Islet-1, Mec-3) kinase pathways [62] . Highlighting the significance of this pathway in PAH, mutations have been reported (although less commonly) in other genes in BMP/ TGF (transforming growth factor) beta signalling, including genes encoding activin A receptor type IIlike kinase-1 (ALK1/ACVRL1), endoglin (ENG), mothers against decapentaplegic (SMAD)-4 and SMAD8 [24, 25] . Exome sequencing has also led to the identification of other susceptibility genes, including caveolin-1 (CAV1) and potassium twopore domain channel subfamily K member 3 (KCNK3) [63] , but mutations in non-BMPR2 genes account for <5% of PAH cases [64] .
There is interest in identifying common polymorphisms that could represent a 'second hit', influencing the presentation and severity of the PAH. For example, variants in the noncoding promoter region of the prostacyclin synthase (PGIS) gene may be protective in the development of PAH in unaffected BMPR2 carriers [65] . Mutations in genes such as potassium voltage-gated channel subfamily A member 5 (KCNA5) or in the noncoding regions of the BMPR2 gene also have the potential to affect the onset and severity of the disease process [66] [67] [68] [69] . In addition, variants in endostatin (Col18a1) [70] and the endothelin-1 pathway gene GNG2 [71] are associated with clinical outcomes in PAH and may influence the response to treatment. Studies in large populations of IPAH/HPAH patients are underway, such as the UK National Institute of Health Research Biomedical Research Centres Inherited Diseases Genetic Evaluation (BRIDGE) consortium and US National Biological Sample and Data Repository for PAH, to assess the prevalence of both common and rare variants in PAH [72] .
The right ventricular (RV) -pulmonary circulation as a cardiovascular unit RV function determines survival in PAH [6, 26, 73] . Initially, RV hypertrophy compensates for the increased pressure afterload from raised pulmonary vascular resistance but the chronic Fig. 1 Mitochondrial energy metabolism. The three main energy pathways in the mitochondria are shown including fatty acid/beta oxidation (green), glucose oxidation/aerobic glycolysis (blue) and glutaminolysis (purple) which feed into the tricarboxylic acid (TCA) cycle (pink). Acetyl-coA produces *citrate which is transported from the mitochondria to the cytosol where it inhibits phosphofructokinase (PFK) and glucose oxidation (Randle effect). Increased pyruvate dehydrogenase kinase (PDK) inhibits pyruvate dehydrogenase (PDH) and glucose oxidation, leading to aerobic glycolysis and the generation of lactate (Warburg effect). Dichloroacetate (DCA) directly inhibits PDK to restore glucose oxidation. Drugs such as ranolazine (RAN) and trimetazidine (TMZ) inhibit fatty acid oxidation. *citrate is transported from the mitochondria to the cytosol where it inhibits phosphofructokinase (PFK). GLUT1, glucose transporter 1; glucose-6P, glucose 6 phosphate; HK1/2, hexokinase 1/2; CoA, co-enzyme A; SOD2, superoxide dismutase-2; HIF-1 a, hypoxia-inducible factor-1a; Ca2+, calcium; CPT1/2, carnitine palmitoyltransferase 1/2; FATP1, fatty acid transport protein 1.
elevation of pressure-load leads to RV ischaemia, impaired RV ejection fraction and RV failure [74] . In addition, measures of right ventriculararterial coupling, taking into account afterload, predict survival in patients with PAH [75] . The development of RV failure can vary between patients, despite having similar degrees of RV hypertrophy and pulmonary pressures, with the RV progressively dilating and decompensating more rapidly in some patients than others [76] [77] [78] . Understanding the molecular basis for adaptation of the RV, predicting RV dysfunction clinically and targeting it therapeutically form a key aspect of the management and treatment of PAH.
Circulating biomarkers -providing insight into the disease and tools for diagnosis and monitoring
There remains considerable interest in identifying accessible noninvasive biomarkers that will assist the clinical management of PAH. Regular clinical assessment is required to evaluate disease progression, response to therapy and prognosis. This includes using multiple clinical parameters and the application of risk equations, although these were designed to gauge prognosis at diagnosis and poorly predict outcomes for individual patients [79] . Haemodynamic measurements, both at baseline (diagnosis) and during followup, are established predictors of disease severity and survival in PAH patients, with right atrial pressure, cardiac index and mixed venous oxygen saturation being the most robust haemodynamic indices of right ventricular function and prognosis [80] [81] [82] [83] . However, patients with PAH do not often receive regular follow-up cardiac catheterizations due to the invasive nature of the procedure, and so noninvasive markers that predict disease progression and survival are of key importance.
World Health Organization functional class (WHO-FC) is a predictor of survival in PAH patients [84, 85] and worsening WHO-FC is a marker of disease progression [82] . Six-minute walk distance (6MWD) is readily measurable at a clinic visit and is a prognostic indicator in PAH [84] , but it is limited by the effect of multiple confounding factors such as comorbidities and age. It remains the most commonly used clinical trial end-point in PAH although a meta-analysis of trial data showed a change in 6MWD does not predict disease progression and survival [86] . Both measures lack complete objectivity and hence may differ between centres and for reasons independent of PH severity.
Measurements of RV function derived from imaging modalities such as cardiac MRI (CMR) or echocardiography predict survival in PAH patients [78, [87] [88] [89] [90] . Although many patients undergo CMR at diagnosis, it is often not repeated due to the expense of the procedure. There remains scope for a robust and readily measurable circulating marker to predict survival in PAH.
The most widely used and accepted circulating biomarker is N-terminal pro-brain natriuretic peptide (NT-proBNP) [6] . It is of limited use as a diagnostic marker as it lacks disease specificity, but has value as a prognostic marker as circulating levels, particularly changes in circulating levels within an individual, reflect disease progression and functional and haemodynamic impairment in PAH patients [82, [91] [92] [93] [94] .
A wide range of other circulating factors have been investigated for risk stratification in PAH. Studies have reported on markers of inflammation (e.g. Creactive protein, interleukin-6), renal impairment (e.g. creatinine, cystatin 2), liver dysfunction (e.g. bilirubin), vascular remodelling (e.g. angiopoietin-2), myocardiocyte strain (e.g. soluble suppression of tumorigenicity-ST2), iron deficiency (e.g. red cell distribution width -RDW) and microRNAs (e.g. microRNA-150) [6, 93, [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] . The possibility that factors that report on different components of the pathology of PAH might be combined to better effect merits careful evaluation.
The availability of high-throughput platform technologies has allowed broad unbiased screens of biological fluids for molecules related to the disease. One such approach has been the use of metabolomics. Nuclear magnetic resonance spectroscopy and mass spectrometry allows the simultaneous assessment of thousands of low molecular weight metabolites from lung tissue, plasma and urine samples. A small study of 20 PAH patients and controls used an untargeted metabolomics platform and showed changes in circulating metabolites such as increased lactate, free fatty acids and glutamine in PAH patients, supporting a shift to aerobic glycolysis [106] . A targeted analysis of 105 circulating plasma metabolites in PAH, primarily amino acids, nucleosides and their derivatives showed abnormal levels of tryptophan, purine and TCA cycle metabolites correlated to haemodynamic measures [55] . A recent study of 1416 circulating metabolites in PAH showed evidence of increased circulating modified nucleosides (N2,N2-dimethylguanosine, N1-methylinosine), TCA cycle intermediates (malate, fumarate), glutamate, fatty acid acylcarnitines and polyamine metabolites and decreased levels of steroids, sphingomyelins and phosphatidylcholines characteristic of patients with PAH [57] . Changes in an individual patient's metabolite levels over time were also associated with improved survival, and patients defined as vasoresponders (who have excellent outcomes on calcium channel blocker therapies) demonstrated metabolic profiles more similar to healthy controls than other patients. Further work is needed to better understand how these measurements may have clinical utility but in addition to monitoring the disease, this approach can provide insight into novel therapeutic pathways. For example, targeting alterations in energy metabolism in PAH or correcting translational regulation in PAH may provide future therapeutic options in PAH [57] .
The treatment of PAH -implementing a paradigm shift in therapy
Patients who retain vasoreactivity (>90%) to an acute vasodilator challenge show marked improvements in quality of life and survival on long-term oral calcium channel blocker therapy [6, 107] . The majority of patients are not 'vasoresponders' and commence targeted treatments for PAH, alongside supportive treatments such as diuretics, focused on pharmacologically regulating the activity of three vasoactive signalling pathways -the prostacyclin-cAMP, nitric oxide-cGMP-PDE5 and endothelin pathways [6, 108, 109] .
Guidelines for the use of these expensive therapies are revised at regular intervals to take account of new treatments (e.g. soluble guanylate cyclase stimulators) [110] and new evidence. The latest guidelines are available online [6] , and the next likely revision will follow a meeting of experts in the field in February 2018 (http:// wsph2018.com). The current debate is whether to start with dual therapy (a PDE5 inhibitor and endothelin receptor antagonist) or whether to proceed stepwise, starting with one and adding or replacing with the other. The nuance on this is whether the choice of agents in the combination matter -given that the trial evidence of benefit comes from the combination of tadalafil and ambrisentan [111] .
The first-generation endothelin receptor antagonists and PDE5 inhibitors were approved on the basis of an improvement in 6MWD. More recent pivotal clinical trials have used a composite endpoint that includes time to clinical worsening and death. There is some evidence from meta-analyses, and these later studies that targeted treatments improve survival. But the need to arrest and preferably reverse the course of the disease remains a therapeutic challenge. One approach has been to initiate treatment with three agents at once -prostacyclin, endothelin receptor antagonist and PDE5 inhibitor -to achieve a rapid reduction in pulmonary artery pressure and relieve the RV workload in patients with severe disease. Early data look very encouraging [112] . But although the licensed therapies have some effect on vascular cell proliferation in vitro, there remains a keen interest in identifying drugs which target the structural remodelling with greater potency. The results to date with tyrosine kinase inhibitors, statins and serotonin antagonists have disappointed [113] .
Although the translation of preclinical studies to patients is a significant challenge [113, 114] , there is a long list of potential new therapies. Whilst many are still undergoing preclinical investigation, several are currently in phase II clinical trials. These include compounds that target mitochondrial and metabolic dysfunction (dichloroacetate, bardoxolone methyl), inflammation and immunity (rituximab, tocilizumab and ubenimex), BMPR2 signalling (tacrolimus), and iron deficiency (ferinject) (Fig. 2) [29, [115] [116] [117] . Pulmonary artery denervation is also being investigated as a potential interventional therapy [116] , and recent advances in epigenetics, stem cells and gene editing offer future translational advances in the treatment of PAH [72, 118] .
The wide range of potential new treatments coupled to the shortage of patients for clinical trials has created a problem and the need to prioritize treatments for investigation. To address this, we must turn to 'omic' technologies and the concept of personalized medicine.
The application of 'Omic' technologies to pulmonary hypertension
It is widely appreciated that PAH, even IPAH, is a heterogeneous condition. Patients with similar clinical manifestations vary markedly in their outcomes and responses to therapy. The clinical classification is a blunt tool for selecting appropriate treatment, and we need to do better. A systems approach is required to understand the complex genetic, epigenetic and environmental influences and the interactions of molecular pathways that underlie patient differences. The integration of data obtained from genomics, transcriptomics, proteomics and metabolomics combined with clinical phenotype information offers the potential of a comprehensive overview of the molecular basis of the disease process. This 'deep molecular phenotype' provides the granularity to identify key signalling pathways that are altered in the disease and assess potentially 'druggable' targets. It also provides biomarkers that inform treatment options by predicting an individual's response to therapy (see Fig. 3 ) and/or a means of monitoring response [72, 119, 120] .
Another area in which 'omics' analyses have great potential utility is in the identification of drugs, even repurposing of drugs approved for other conditions [121, 122] . A disease signature, for example changes in gene and/or protein expression levels in patient tissue samples, can be compared with the effects of libraries of drugs on gene and protein expression in relevant model systems (animal and cell models). Drugs that restore or rebalance the pattern of gene and protein expression in these model systems would then be candidates for PAH therapies (Fig. 4) .
Key to the success of this approach is access to clinically characterized patient cohorts linked to well-curated sample biobanks. This has driven expert centres to collaborate at both the national and international level to share protocols and harmonize data collection to power meaningful analyses. It has also stimulated calls for large clinical trials to collect samples at baseline and study end, as these sizeable cohorts of wellphenotyped patients defined by clear study entry criteria provide a precious resource for 'omics' analyses to characterize the molecular make-up of responders and nonresponders to drug treatment.
Even so, the integration of multiple 'omics' data sets remains a challenge [123, 124] . Whilst several software tools are available with large reference databases of molecular interactions, they have limitations, in particular incomplete biological pathway annotation [124] . Exome data are better annotated than whole-genome sequence data and the regulation of protein levels is better understood than protein-protein interactions, whilst epigenetic pathways, post-translational protein modifications and metabolome data represent another level of complexity [123] . The computational analysis of multiple data sets and modelling of the dynamic interactions of genes, proteins and metabolites through networks such as the Human Interactome Project (http://interactome.dfci.harvard.edu/H_sa piens/) allows for prioritization and identification of key molecules [125] [126] [127] [128] . For example, a network built around pathogenic pathways in PAH has been used to prioritize microRNAs, highlighting microRNA-21 which regulates Rho/Rho-kinase and BMP signalling [129] . This approach can be applied to other 'omics' data sets to prioritize pathogenic targets in PAH.
Conclusions
The management of patients with PAH has advanced considerably over the past 25 years, with improvements in functional status, quality of life and survival. In addition to their therapeutic effects, drugs are powerful tools for dissecting disease mechanisms; responders and nonresponders to a given treatment have a story to tell. Coupled with a deeper understanding of the molecular pathology of the disease process, the clinical view of PAH will continue to evolve. The idea that molecular profiling of large cohorts of PAH patients will provide deeper phenotypic characterization of patients and a richer base from which to develop and target new signalling pathways tailored to each patient's needs has momentum. Delivery on this strategy will depend on international collaboration to give sufficient Drug 2 selected Fig. 4 Repurposing drugs by matching effects of disease signatures. Matching disease signature profiles to the effects of drugs on those profiles in model systems could facilitate identification and repurposing of drugs approved for other conditions. In the example above, a disease signature based on gene, protein and metabolite expression was established in samples from a diseased population, for example pulmonary arterial hypertension. This was compared to the effects of 4 drugs on the same genes, proteins and metabolites in model systems. The profile of drug 2 influences the 'disease signature', restoring levels towards that seen in health, and could be selected for further study as a treatment for the PAH. power for network analysis to give confidence in the results. Success will inform and likely shorten drug development by enabling patient selection for clinical trials and monitoring response to treatment. It would be a 'win-win' scenario.
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